Luminex Corporation (NASDAQ:LMNX) will hold its 3Q20 earnings conference call with the financial community on 5th November 2020 at 5:00 PM Eastern Time.
The conference call will be webcast live on Internet at www.luminexcorp.com
Earnings Expectation
Luminex Corporation is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.20 per share from revenue of $ 105.02 million. Looking ahead, the full year income are expected at $ 0.80 per share on the revenues of $ 420.61 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 106.00 million ~ $ 106.00 million
Full Year 2020 topline are forecasted in a range of$ 352.00 million ~ $ 362.00 million
Click Here For More Historical Outlooks Of Luminex Corporation
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism.
